About: Piboserod

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Piboserod is a selective 5-HT4 receptor antagonist which was marketed and manufactured by GlaxoSmithKline (GSK) under the trade name Serlipet for the management of atrial fibrillation and irritable bowel syndrome. In 2007 the Norwegian company Bio-Medisinsk Innovasjon AS (BMI) completed a clinical phase II study to investigate the effect of piboserod in patients with chronic heart failure.

Property	Value
dbo:abstract	Piboserod is a selective 5-HT4 receptor antagonist which was marketed and manufactured by GlaxoSmithKline (GSK) under the trade name Serlipet for the management of atrial fibrillation and irritable bowel syndrome. In 2007 the Norwegian company Bio-Medisinsk Innovasjon AS (BMI) completed a clinical phase II study to investigate the effect of piboserod in patients with chronic heart failure. (en)
dbo:alternativeName	Serlipet (en)
dbo:casNumber	152811-62-6
dbo:chEMBL	356359
dbo:fdaUniiCode	4UQ3S81B25
dbo:pubchem	177336
dbo:thumbnail	wiki-commons:Special:FilePath/Piboserod.png?width=300
dbo:wikiPageID	18861000 (xsd:integer)
dbo:wikiPageLength	3539 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1102283665 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Antagonist dbc:GSK_plc_brands dbc:Indoles dbc:Piperidines dbr:GlaxoSmithKline dbr:Animal_model dbr:Heart_failure dbr:Irritable_bowel_syndrome dbr:5-HT4_receptor dbc:Carboxamides dbc:5-HT4_antagonists dbr:Atrial_fibrillation dbr:Serotonin dbr:Oslo_University dbr:Betablocker dbr:Clinical_studies dbr:Cardiac_ventricle dbr:Expression_(genetics)
dbp:atcPrefix	none (en)
dbp:c	22 (xsd:integer)
dbp:casNumber	152811 (xsd:integer)
dbp:chembl	356359 (xsd:integer)
dbp:chemspiderid	154413 (xsd:integer)
dbp:h	31 (xsd:integer)
dbp:iupacName	N--3,4-dihydro-2H-oxazinoindole-10-carboxamide (en)
dbp:iupharLigand	225 (xsd:integer)
dbp:legalStatus	Clinical phase II (en)
dbp:n	3 (xsd:integer)
dbp:o	2 (xsd:integer)
dbp:pubchem	177336 (xsd:integer)
dbp:routesOfAdministration	Oral (en)
dbp:smiles	CCCCN1CCCCC1 (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	KVCSJPATKXABRQ-UHFFFAOYSA-N (en)
dbp:tradename	Serlipet (en)
dbp:unii	4 (xsd:integer)
dbp:verifiedfields	changed (en)
dbp:verifiedrevid	408035930 (xsd:integer)
dbp:watchedfields	changed (en)
dbp:wikiPageUsesTemplate	dbt:GlaxoSmithKline dbt:Drugbox dbt:Reflist dbt:Serotonergics dbt:Short_description dbt:Cascite dbt:Chemspidercite dbt:Ebicite dbt:Fdacite dbt:Stdinchicite
dcterms:subject	dbc:GSK_plc_brands dbc:Indoles dbc:Piperidines dbc:Carboxamides dbc:5-HT4_antagonists
gold:hypernym	dbr:Antagonist
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatAmides yago:Abstraction100002137 yago:Amide114724264 yago:Chemical114806838 yago:Compound114818238 yago:LanguageUnit106284225 yago:Material114580897 yago:Matter100020827 yago:Name106333653 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Relation100031921 yago:WikicatGlaxoSmithKlineBrands dbo:Drug yago:Substance100019613 yago:TradeName106845599 umbel-rc:DrugProduct
rdfs:comment	Piboserod is a selective 5-HT4 receptor antagonist which was marketed and manufactured by GlaxoSmithKline (GSK) under the trade name Serlipet for the management of atrial fibrillation and irritable bowel syndrome. In 2007 the Norwegian company Bio-Medisinsk Innovasjon AS (BMI) completed a clinical phase II study to investigate the effect of piboserod in patients with chronic heart failure. (en)
rdfs:label	Piboserod (en)
owl:sameAs	freebase:Piboserod yago-res:Piboserod wikidata:Piboserod dbpedia-fa:Piboserod dbpedia-sh:Piboserod dbpedia-sr:Piboserod https://global.dbpedia.org/id/4w4qH
prov:wasDerivedFrom	wikipedia-en:Piboserod?oldid=1102283665&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Piboserod.png
foaf:isPrimaryTopicOf	wikipedia-en:Piboserod
is dbo:wikiPageRedirects of	dbr:Serlipet
is dbo:wikiPageWikiLink of	dbr:5-HT4_receptor dbr:5-HT_receptor dbr:C22H31N3O2 dbr:Serlipet
is foaf:primaryTopic of	wikipedia-en:Piboserod